The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NCI 8628: A randomized phase II study of ziv-aflibercept (Z) and high-dose interleukin-2 (HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanoma—Efficacy and biomarker study.
Madeeha Ashraf
No relevant relationships to disclose
John M. Kirkwood
Research Funding - Prometheus
Marc S. Ernstoff
No relevant relationships to disclose
Hussein Abdul-Hassan Tawbi
No relevant relationships to disclose
Paul Henry Frankel
No relevant relationships to disclose
Nora Ruel
No relevant relationships to disclose
Kari Lynn Kendra
No relevant relationships to disclose
Thomas Olencki
No relevant relationships to disclose
Nikhil I. Khushalani
No relevant relationships to disclose
Theodore F. Logan
No relevant relationships to disclose
Kim Allyson Margolin
No relevant relationships to disclose
Alice P. Chen
No relevant relationships to disclose
Ahmad A. Tarhini
Consultant or Advisory Role - Prometheus
Research Funding - Prometheus